Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
Key Highlights
- ➤Q3 revenue $8.9 million, up 20% year over year
- ➤Convertible financing totals up to $24 million, with $12 million upfront
- ➤Cash balance $4.0 million at September 30, 2026
- ➤Adjusted operating loss widened to $5.1 million from $2.5 million
- ➤Disposable-order backlog reached approximately $1.9 million amid supply constraints
Expert Statements
David Fischel, Chairman and CEO of Stereotaxis
“Our near-term priority is to drive forward two major business model transformations”
David Fischel, Chairman and CEO of Stereotaxis
“The first is shifting from capital systems that require long sales and construction timelines, to having a portfolio of systems that are significantly more accessible and scalable.”
David Fischel, Chairman and CEO of Stereotaxis
“The second is developing and commercializing a portfolio of disposable interventional catheters that enhance the value of our robots and provide a robust recurring revenue opportunity.”
David Fischel, Chairman and CEO of Stereotaxis
“System revenue of $3 million in the quarter was up 60% compared to last year, benefiting from partial revenue recognition from the first GenesisX system in the US, the first Genesis system in China, and multiple Synchrony digital operating room systems in the US.”
David Fischel, Chairman and CEO of Stereotaxis
“Recurring revenue increased 6% over the previous year with a significant increase in revenue from our new portfolio of robotically-navigated catheters, countered by general pressure on procedures due to supply shortages.”
David Fischel, Chairman and CEO of Stereotaxis
“We entered the fourth quarter with a backlog of approximately $1.9 million in disposable orders we did not convert to revenue because of supply constraints.”
David Fischel, Chairman and CEO of Stereotaxis
“In parallel to our commercial efforts, we continue to invest in a broad pipeline of innovations that expand our technology into a platform across endovascular surgery, enhance our competitiveness in electrophysiology, and deliver digital connectivity, automation and intelligence to the operating room.”
David Fischel, Chairman and CEO of Stereotaxis
“We were pleased during the past quarter to close the acquisition of Robocath and announce a collaboration with Canon.”
ST. LOUIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the third quarter ended September 30, 2026.
“Our near-term priority is to drive forward two major business model transformations,” said David Fischel, Chairman and CEO. “The first is shifting from capital systems that require long sales and construction timelines, to having a portfolio of systems that are significantly more accessible and scalable. The second is developing and commercializing a portfolio of disposable interventional catheters that enhance the value of our robots and provide a robust recurring revenue opportunity.”
Get started
Create a free account to read the full story.